The registry included 2,095 patients who were treated for 2.348 lesions in different cohorts. The results showed low total MACE rate, low myocardial infarction and low cardiac death rate.
Vice President of B. Braun Vascular Systems Gerd Wacker said in the report that the findings show that SeQuent Please can be considered a reasonable alternative to drug-eluting stents for some patients with artery disease.
Related Articles on B. Braun:
B. Braun Releases Enhanced Offerings for Hemodialysis System
B. Braun Medical’s Aesculap Academy Launches Regional Anesthesia Website
Aesculap Acquires Aragon Surgical
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
